These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9548542)

  • 1. Development and activities of a new melphalan prodrug designed for tumor-selective activation.
    Kerr DE; Li Z; Siemers NO; Senter PD; Vrudhula VM
    Bioconjug Chem; 1998; 9(2):255-9. PubMed ID: 9548542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.
    Siemers NO; Kerr DE; Yarnold S; Stebbins MR; Vrudhula VM; Hellström I; Hellström KE; Senter PD
    Bioconjug Chem; 1997; 8(4):510-9. PubMed ID: 9258449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma.
    Svensson HP; Frank IS; Berry KK; Senter PD
    J Med Chem; 1998 Apr; 41(9):1507-12. PubMed ID: 9554883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs.
    Kerr DE; Schreiber GJ; Vrudhula VM; Svensson HP; Hellström I; Hellström KE; Senter PD
    Cancer Res; 1995 Aug; 55(16):3558-63. PubMed ID: 7627964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering.
    McDonagh CF; Beam KS; Wu GJ; Chen JH; Chace DF; Senter PD; Francisco JA
    Bioconjug Chem; 2003; 14(5):860-9. PubMed ID: 13129388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of recombinant and synthetically formed monoclonal antibody-beta-lactamase conjugates for anticancer prodrug activation.
    Kerr DE; Vrudhula VM; Svensson HP; Siemers NO; Senter PD
    Bioconjug Chem; 1999; 10(6):1084-9. PubMed ID: 10563779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologically specific activation of a cephalosporin derivative of mitomycin C by monoclonal antibody beta-lactamase conjugates.
    Vrudhula VM; Svensson HP; Senter PD
    J Med Chem; 1997 Aug; 40(17):2788-92. PubMed ID: 9276025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolidase, a potential enzyme target for melanoma: design of proline-containing dipeptide-like prodrugs.
    Mittal S; Song X; Vig BS; Landowski CP; Kim I; Hilfinger JM; Amidon GL
    Mol Pharm; 2005; 2(1):37-46. PubMed ID: 15804176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.
    Svensson HP; Vrudhula VM; Emswiler JE; MacMaster JF; Cosand WL; Senter PD; Wallace PM
    Cancer Res; 1995 Jun; 55(11):2357-65. PubMed ID: 7757987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).
    Alderson RF; Toki BE; Roberge M; Geng W; Basler J; Chin R; Liu A; Ueda R; Hodges D; Escandon E; Chen T; Kanavarioti T; Babé L; Senter PD; Fox JA; Schellenberger V
    Bioconjug Chem; 2006; 17(2):410-8. PubMed ID: 16536473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proline prodrug of melphalan, prophalan-L, demonstrates high therapeutic index in a murine melanoma model.
    Mittal S; Tsume Y; Landowski CP; Lee KD; Hilfinger JM; Amidon GL
    Eur J Pharm Biopharm; 2007 Nov; 67(3):752-8. PubMed ID: 17560100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-beta-lactamase conjugates.
    Vrudhula VM; Svensson HP; Kennedy KA; Senter PD; Wallace PM
    Bioconjug Chem; 1993; 4(5):334-40. PubMed ID: 8274516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Derivatives of melphalan designed to enhance drug accumulation in cancer cells.
    Kupczyk-Subotkowska L; Tamura K; Pal D; Sakaeda T; Siahaan TJ; Stella VJ; Borchardt RT
    J Drug Target; 1997; 4(6):359-70. PubMed ID: 9239576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug.
    Rodrigues ML; Presta LG; Kotts CE; Wirth C; Mordenti J; Osaka G; Wong WL; Nuijens A; Blackburn B; Carter P
    Cancer Res; 1995 Jan; 55(1):63-70. PubMed ID: 7805042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug.
    Cheng TL; Wei SL; Chen BM; Chern JW; Wu MF; Liu PW; Roffler SR
    Br J Cancer; 1999 Mar; 79(9-10):1378-85. PubMed ID: 10188879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
    Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
    J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective enhancement of antitumor activity of N-acetyl melphalan upon conjugation to monoclonal antibodies.
    Smyth MJ; Pietersz GA; McKenzie IF
    Cancer Res; 1987 Jan; 47(1):62-9. PubMed ID: 3791221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB.
    Pollack VA; Alvarez E; Tse KF; Torgov MY; Xie S; Shenoy SG; MacDougall JR; Arrol S; Zhong H; Gerwien RW; Hahne WF; Senter PD; Jeffers ME; Lichenstein HS; LaRochelle WJ
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):423-35. PubMed ID: 17541593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
    Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
    J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
    Caffrey PB; Zhang Y; Frenkel GD
    Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.